SCHEMBL24547743

SCHEMBL24547743

Cn1ncc2c1c1ccc(F)cc1n2C(=O)C1CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.38
SMO Q99835 1/20 0.37
HTR2C P28335 1/20 0.35
RORC P51449 1/20 0.35
GRM5 P41594 1/20 0.34
KDM2B Q8NHM5 1/20 0.34
CNR1 P21554 1/20 0.34
TRPV1 Q8NER1 1/20 0.34
ALDH1A1 P00352 2/20 0.34
SSTR4 P31391 1/20 0.34
OPRM1 P35372 1/20 0.34
OPRD1 P41143 1/20 0.34
OPRK1 P41145 1/20 0.34
OGFRL1 Q5TC84 1/20 0.34
TP53 P04637 1/20 0.34
ABL1 P00519 1/20 0.33
PARG Q86W56 1/20 0.33
MAPK1 P28482 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GRIN2B Q13224 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24547686 0.91 HSD11B1 (0.40) HSD11B1SMOHTR2CRORCGRM5
SCHEMBL24547757 0.83 ELANE (0.45) ALDH1A1MAPK1
SCHEMBL24547660 0.83 ELANE (0.45) ALDH1A1MAPK1
SCHEMBL24547758 0.82 ELANE (0.46) ALDH1A1MAPK1
SCHEMBL24547762 0.72 HSD17B10 (0.41) CNR1ALDH1A1MAPK1
SCHEMBL24547633 0.70 RIPK1 (0.38) CNR1ALDH1A1SSTR4MAPK1SMN1; SMN2
SCHEMBL24547763 0.68 TFPI2 (0.42) HSD11B1ALDH1A1TP53MAPK1SMN1; SMN2
SCHEMBL24547678 0.66 ELANE (0.42) ALDH1A1MAPK1
SCHEMBL24547737 0.66 LMNA (0.50) ALDH1A1SMN1; SMN2
SCHEMBL24547656 0.66 ELANE (0.46) ALDH1A1TP53MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067654-A1 OXYTOCIN RECEPTOR MODULATORS Kinoxis Therapeutics Pty Ltd (AU) 2024-02-29 US disclosed
US-20240067654-A1 OXYTOCIN RECEPTOR MODULATORS Kinoxis Therapeutics Pty Ltd (AU) 2024-02-29 US disclosed
WO-2022126179-A1 OXYTOCIN RECEPTOR MODULATORS THE UNIVERSITY OF SYDNEY (AU) 2022-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067654-A1 OXYTOCIN RECEPTOR MODULATORS OXTR, AVPR1B, AVPR1A HSD11B1 313/4885SMO 4223/4885HTR2C 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.